Use of lycorine hydrochloride in the preparation of a medicament for inhibiting neointimal hyperplasia

By inhibiting the MAPK signaling pathway through lycorine hydrochloride, the problem of neointimal hyperplasia in blood vessels after PCI is solved, providing a drug to inhibit the proliferation and migration of vascular smooth muscle cells, and has the potential to prevent and treat restenosis and in-stent thrombosis.

CN117503770BActive Publication Date: 2026-06-26XINXIANG MEDICAL UNIV
3 Cites 0 Cited by

Patent Information

Application Number
CN202311486489.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-09
Publication Date
2026-06-26
Estimated Expiration
2043-11-09

AI Technical Summary

Technical Problem

Restenosis and in-stent thrombosis after PCI are difficult to effectively inhibit due to neointimal hyperplasia caused by the proliferation and migration of vascular smooth muscle cells.

Method used

By using lycorine hydrochloride, the proliferation and migration of vascular smooth muscle cells induced by platelet-derived growth factor-BB were intervened through the MAPK signaling pathway, and a drug was prepared to inhibit intravascular neointimal hyperplasia.

Benefits of technology

It significantly inhibited vascular intimal hyperplasia induced by left common carotid artery ligation. In vitro experiments showed that lycorine hydrochloride could inhibit PDGF-BB-induced proliferation, migration and phenotypic transformation of VSMCs, providing a potential drug for the prevention and treatment of restenosis and in-stent thrombosis after PCI.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.
Need to check novelty before this filing date? Find Prior Art